FcRn and Myasthenia Gravis: Pathophysiology episode artwork

EPISODE · Nov 7, 2024 · 13 MIN

FcRn and Myasthenia Gravis: Pathophysiology

from Rare Disease Discussions · host CheckRare Editors

Jointly Provided by American Academy of CME Inc and CheckRare CE Inc.Support for this accredited continuing education activity has been made possible through an educational grant from argenx US Inc.and UCB.Estimated time to complete: 0.25 hoursStart date: November 7, 2024End date: November 6, 2025This quarter-hour CME-accredited program, hosted by Richard J. Nowak, MD, MS, explains the role of  neonatal fragment crystallizable receptor (FcRn) in myasthenia gravis (MG).To obtain CME credit, visit https://checkrare.com/learning/p-fcrn-and-myasthenia-gravis-pathophysiology/ Activity FacultyRichard J. Nowak, MD, MSDirector, Program in Clinical & Translational Neuromuscular Research (CTNR) Director, Yale Myasthenia Gravis Clinic Associate Professor of Neurology Division of Neuromuscular MedicineDepartment of Neurology Yale School of Medicine New Haven, CTTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology and ophthalmology who may be involved in the diagnosis and care of individuals with MG. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able toDescribe the role of FcRn in MG.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty EducatorDr. Nowak discloses the following relevant financial relationships with ineligible companies:Advisory Board/Consultant: Alexion (part of AstraZeneca), argenx, Amgen, Cour Pharmaceuticals, Immunovant, Janssen, UCBGrant/Research Support: Alexion (part of AstraZeneca), argenx, Amgen, Cour Pharmaceuticals, Immunovant, Janssen, UCBPlanners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.Hardware/Software Requirements Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection.Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare’s privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: [email protected]© 2024. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s). Rare Discussions is produced by CheckRare, the leading multimedia platform dedicated to advancing education, awareness, and innovation across the rare disease community.Explore additional physician interviews, podcasts, CME activities, and rare disease resources at CheckRare.com.Subscribe to the CheckRare Podcast Network for expert conversations, weekly news, accredited education, and the latest advances across the rare disease community.Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.

Episode metadata supplied by the publisher feed · Published Nov 7, 2024

Embed this episode

Jointly Provided by American Academy of CME Inc and CheckRare CE Inc. Support for this accredited continuing education activity has been made possible through an educational grant from argenx US Inc.and UCB. Estimated time to complete: 0.25 hours Start date: November 7, 2024 End date: November 6, 2025 This quarter-hour CME-accredited program, hosted by Richard J. Nowak, MD, MS, explains the role of neonatal fragment crystallizable receptor (FcRn) in myasthenia gravis (MG). To obtain CME credit, visit https://checkrare.com/learning/p-fcrn-and-myasthenia-gravis-pathophysiology/ Activity Faculty Richard J. Nowak, MD, MS Director, Program in Clinical & Translational Neuromuscular Research (CTNR) Director, Yale Myasthenia Gravis Clinic Associate Professor of Neurology Division of Neuromuscular Medicine Department of Neurology Yale School of Medicine New Haven, CT Target Audience This activity has been designed to meet the educational needs of physicians specializing in neurology and ophthalmology who may be involved in the diagnosis and care of individuals with MG. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning Objectives After participating in the activity, learners should be better able to Describe the role of FcRn in MG. Accreditation and Credit Designation In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physicians American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPs Other members of the care team will receive a certificate of participation. Disclosure Statement According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated. Disclosure of relevant financial relationships are as follows: Faculty Educator Dr. Nowak discloses the following relevant financial relationships with ineligible companies: Advisory Board/Consultant: Alexion (part of AstraZeneca), argenx, Amgen, Cour Pharmaceuticals, Immunovant, Janssen, UCB Grant/Research Support: Alexion (part of AstraZeneca), argenx, Amgen, Cour Pharmaceuticals, Immunovant, Janssen, UCB Planners for this activity have no relevant financial relationships with any ineligible companies. This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information. Method of...

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

FcRn and Myasthenia Gravis: Pathophysiology

0:00 13:08

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of Rare Disease Discussions?

This episode is 13 minutes long.

When was this Rare Disease Discussions episode published?

This episode was published on November 7, 2024.

Can I download this Rare Disease Discussions episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!